

# HOT TOPICS IN CARDIOLOGIA 2024

**27 e 28 Novembre 2024**

Villa Doria D'Angri - Via F. Petrarca 80,  
Napoli


# NEW INSIGHTS IN CARDIOLOGY: INTELLIGENZA ARTIFICIALE IN CARDIOLOGIA

**Prof. Giovanni Esposito**



Presidente Scuola di Medicina e Chirurgia  
Università degli Studi di Napoli "Federico II"  
Direttore UOC Cardiologia, AOU "Federico II"  
Past President SICI-GISE



# CAUSES OF DEATH IN US: 2019 - 2023




Ahmad F. *JAMA* 2024, in press




Vaduganathan M et al. *J Am Coll Cardiol.* 2022;80(25):2361-2371.

# DECLINE IN DEATHS FROM CARDIOVASCULAR DISEASE IN RELATION TO SCIENTIFIC ADVANCES



Adapted from Nabel EG and Braunwald E., *N Eng J Med* 2012;366:54-63

# ARTIFICIAL INTELLIGENCE: HISTORY AND DEFINITION



«A computer would deserve to be called intelligent if it could deceive a human into believing that it was human.  
Can machines think?»

Alan Turing, 1950



## ARTIFICIAL INTELLIGENCE

is a tool that uses machines to learn and perform complex tasks

## MACHINE LEARNING

is an algorithm that can find solutions to problems using the data provided and improve performance by the exposure to more data







## DEEP LEARNING

uses convolution neural networks to identify patterns and learn information from vast amounts of data

Di Costanzo A, Spaccarotella CAM, Esposito G, Indolfi.  
*J Clin Med.* 2024;13(4):1033.




# ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING




# PATIENT-GENERATED HEALTH DATA (PGHD)

- The efficient application of wearable devices to clinical practice could be facilitated by a **platform** that ingests data from a variety of wearable devices, followed by filtering (identification of clinically true data), display, and annotation, and critical alerting processes.
- The curated data/reports would then be sent to the **electronic health record**.
- Interaction with the data (including ordering and reporting) could remain through the electronic health records to **simplify workflow and minimize the problem of multiple logins**



# ARTIFICIAL INTELLIGENCE: TO ACHIEVE PERSONALIZED THERAPY IN CARDIOLOGY


- Clinical information including patient data, laboratory parameters, and results from clinical examination, large-scale data from registries, imaging data, and patient biometrical data can all be processed by artificial intelligence.
- Resulting models allow for disease phenotyping, enhance diagnostics, improve prognostication, and facilitate treatment decision-making, thus ultimately contributing to a more **personalized therapy** of patients with cardiovascular disease.



Lüscher TF et al. *Eur Heart J*. Published online August 19, 2024.




# ROLE OF ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR MEDICINE



Johnson KW, et al., *J Am Coll Cardiol.* 2018;71(23):2668-2679.



# ADVANCING CARDIOVASCULAR CARE WITH ARTIFICIAL INTELLIGENCE



Jain SS et al. *J Am Coll Cardiol.* 2024;83(24):2487-2496.


# CARDIOVASCULAR ARTIFICIAL INTELLIGENCE BY IMAGING MODALITY

## Electrocardiograms and Wearables



- Detection of structural heart disease from 12-lead ECG
- Detection of atrial fibrillation wearable smartwatch
- Screening for asymptomatic LV dysfunction (LVEF  $\leq 50\%$ )

## Echocardiograms




- Cardiologist agreement on LVEF greater with AI vs sonographer
- Diagnosis of HCM and CA from other causes of LVH
- Novice users assisted to quickly and accurately assess LV

## MRI, Nuclear, CT



- Auto-assess coronary calcium on all CT scans to find untreated CAD
- Perivascular fat attenuation index on Coronary CTA to predict mortality
- AI-based virtual native enhancement replacing LGE on CMR


## Coronary Angiography



- Automated LVEF calculation without requiring ventriculogram
- Prediction of MACE based on plaque morphology on angiography
- Coronary artery stenosis localization and estimation during LHC

*Elias P et al., J Am Coll Cardiol. 2024;83(24):2472-2486.*


# THE EMERGENCE OF ARTIFICIAL INTELLIGENCE IN CARDIOLOGY: CURRENT AND FUTURE APPLICATIONS



Artificial intelligence and cardiology.

Kulkarni P et al. *Curr Cardiol Rev.* 2022;18(3):e191121198124.


# ARTIFICIAL INTELLIGENCE-ENHANCED PATIENT EVALUATION-1



Oikonomou EK et al. Eur Heart J. 2024;45(35):3204-3218.




# ARTIFICIAL INTELLIGENCE-ENHANCED PATIENT EVALUATION-2





Oikonomou EK et al. *Eur Heart J.* 2024;45(35):3204-3218.

# ARTIFICIAL INTELLIGENCE-ENHANCED PATIENT EVALUATION-3



Oikonomou EK et al. *Eur Heart J.* 2024;45(35):3204-3218.











# ARTIFICIAL INTELLIGENCE IN PREVENTIVE CARDIOLOGY

- AI models have shown **superior** performance in **personalized ASCVD risk evaluation** compared to traditional risk scores;
- These models support automated detection of **ASCVD risk markers** (including coronary artery calcium, chest X-ray, mammograms, coronary angiography and CT-scans);
- Large language models are effective in **identifying and addressing gaps and disparities** in ASCVD preventive care.



Parsa S et al., *Curr Atheroscler Rep*. Published online May 23, 2024.

# MACHINE LEARNING VS. ACC/AHA RISK CALCULATOR



**ML Risk Calculator outperformed the ACC/AHA Risk Calculator:**

- Less drug therapy;
- Missing fewer CV events.

# ASSOCIATION BETWEEN MACHINE VISION-BASED BUILT ENVIRONMENT FROM GOOGLE STREET VIEW AND PREVALENCE OF CORONARY ARTERY DISEASE IN U.S CITIES



Feature #2017



Feature #458




Feature #2873




Feature #237

- Neighborhood characteristics derived from Google Street View (GSV) images of 7 U.S. cities (Cleveland, Fremont, Kansas City, Detroit, Bellevue, Brownsville and Denver) were associated with 63% of the variance in prevalence of CAD.
- Compared with a model including age, sex, race, income, education, and composite indices for social determinants of health, addition of GSV features enhanced the association with CAD.




Chen Z et al. Eur Heart J. 2024;45(17):1540-1549.








# GAPS IN CARE OF A PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION AND HEART FAILURE IN A TRADITIONAL EPISODIC CARE MODEL




Spatz ES. et al. N Engl J Med 2024;390:346-56.

# AI-BASED VS. TRADITIONAL TOOLS FOR AF DIAGNOSIS







AI-based methods for the diagnosis of atrial fibrillation have **high sensitivity and specificity** for the detection of AF.




Manetas-Stavarakakis N et al., *J Clin Med.* 2023;12(20):6576.

# WEARABLE DEVICES FOR AF DIAGNOSIS: THE APPLE HEART STUDY



Variable	Notification Subgroup (N = 929)	Non-notification Subgroup (N = 293,015)
New diagnosis — no. (%)		
Atrial fibrillation	404 (43)	3070 (1.0)
Stroke	7 (0.8)	321 (0.1)
TIA	12 (1.3)	498 (0.2)
Heart failure	30 (3.2)	648 (0.2)
Myocardial infarction	10 (1.1)	574 (0.2)
Major bleeding	7 (0.8)	842 (0.3)
Medication use — no. (%)*		
Warfarin	20 (2.2)	265 (0.1)
Direct oral anticoagulant	202 (22)	996 (0.3)
Aspirin	338 (36)	40,774 (14)

# CONTACT FREE DETECTION OF AF FROM VIDEO WITH DEEP-LEARNING




- 20 patients with permanent AF and 24 control individuals in sinus rhythm were recruited;
- Analysis of facial photo-plethysmographic (FPPG) signals from multiple patients concurrently using a single digital camera and a pretrained deep convolutional neural network;
- Pulse irregularity in >50% FPPG segments for each patient was considered positive for AF;
- 64 videos were recorded, each capturing 5 patients simultaneously in 32 different heart-rhythm permutations based on a 5-participant binary (AF/SR) matrix;
- Each patient appeared in 7 videos and 320 individual FPPG signals were analyzed.


Diagnostic Accuracy of Facial Photoplethysmographic in Detecting Atrial Fibrillation

Variable	12-Lead ECG		Total
	AF Present	AF Absent	
FPPG, No. (%) <sup>a</sup>			
Positive	150 (46.9)	3 (0.9)	153
Negative	10 (3.1)	157 (49.1)	167
Total No.	160	160	320





# TEMPORAL PROGRESSION IN AUTOMATED QUANTIFICATION IN ECHOCARDIOGRAPHY



# AI IN ECHOCARDIOGRAPHY

- AI-guided workflow for the initial assessment of cardiac function in echocardiography was non-inferior and even **superior** to the initial assessment by the sonographer.
- Cardiologists required **less time**, substantially changed the initial assessment **less frequently** and were **more consistent** with previous clinical assessments by the cardiologist when using an AI-guided workflow.





Image acquisition







Image analysis




# AI IN CARDIAC MAGNETIC RESONANCE

- AI-guided analysis was **quickly** than human;
- Machine analysis had **superior precision** with more repeatability;
- This translates to a **46%** reduction in required trial sample size using an LVEF endpoint.




	Intra-observer Reproducibility (%)		P-value	Scan-rescan Reproducibility (%)		P-value
	Human	Machine		Human	Machine	
EDV	3.2 (2.6 – 3.8)	0	P<0.001**	5.7 (4.8 – 6.4)	5.4 (4.3 – 6.8)	P=0.04*
ESV	7.6 (6.3–9.1)	0	P<0.001**	10 (8.1 – 11.9)	8.9 (7.6–10.3)	P=0.10
EF	5.1 (3.7-6.4)	0	P<0.001**	6 (5.1-7.0)	4.2 (3.5 – 5.0)	P<0.01*
LVM	3.9 (3.4–4.4)	0	P<0.001**	4.8 (4.1 – 5.6)	3.6 (2.9 – 4.3)	P<0.01*






# AI IN AORTIC STENOSIS EVALUATION




- Using self-supervised pretraining and ensemble learning, a deep learning model was trained to detect severe AS using single-view echocardiography without Doppler imaging.
- The model **maintained high performance** in multiple geographically and temporally distinct cohorts.
- This automated method to detect severe AS using a single TTE view may have relevant implications for point-of-care ultrasound screening by individuals with minimal training in limited resource settings.


# AI IN PRE-TAVR PLANNING: CT-SCAN

## AUTOMATIC DETERMINATION OF AORTIC VALVE ANNULAR PLANE



## AUTOMATIC EVALUATION OF VASCULAR ACCESS








# DIAGNOSTIC PERFORMANCE OF STEMI ON ECG: ECG BUDDY



®



 35 Rhythms

 QCG™ scores and confidence intervals

 Biomarkers

 QCG™ Score Category

1. Critical condition	→ Needs of critical care
2. Acute Coronary Syndrome 3. ST-elevation Myocardial Infarction 4. Miocardial Injury	→ Cardiac Ischemia
5. Pulmonary Edema 6. Large Pericardial Effusion 7. Left Ventricular Dysfunction 8. Right Ventricular Dysfunction 9. Pulmonary Hypertension	→ Heart Function
10. Severe Hyperkalemia	→ Electrolytes

 Interpretation and suggestions

**Sinus Rhythm - 99.7%.**  
Assign the patient to critical care zone.

**This looks like a definite STEMI.** Call Cath. Lab., right now.

**RV dysfunction** is very likely. **LV dysfunction** (LVEF<40%) and pulmonary edema is suspected. Check echocardiography.



# AI-POWERED RAPID IDENTIFICATION OF STEMI: THE ARISE TRIAL



NEJM AI 2024; 1 (7)  
DOI: 10.1056/Aloa2400190

ORIGINAL ARTICLE

## Artificial Intelligence–Powered Rapid Identification of ST-Elevation Myocardial Infarction via Electrocardiogram (ARISE) — A Pragmatic Randomized Controlled Trial



Chin Lin , Ph.D.,<sup>1,2,3,4</sup> Wei-Ting Liu , M.D.,<sup>5</sup> Chiao-Hsiang Chang , M.D.,<sup>5</sup> Chiao-Chin Lee , M.D.,<sup>5</sup> Shi-Chue Hsing , M.D.,<sup>5</sup> Wen-Hui Fang , M.D.,<sup>2,6</sup> Dung-Jang Tsai , Ph.D.,<sup>1,2,7</sup> Kai-Chieh Chen , M.S.,<sup>8</sup> Chun-Ho Lee , M.S.,<sup>3</sup> Cheng-Chung Cheng , M.D.,<sup>5</sup> Yi-Jen Hung , M.D.,<sup>9</sup> Shih-Hua Lin , M.D.,<sup>10</sup> Chien-Sung Tsai , M.D.,<sup>11</sup> and Chin-Sheng Lin , M.D., Ph.D.<sup>1,5</sup>


Received: February 21, 2024; Revised: April 7, 2024; Accepted: April 30, 2024; Published: June 27, 2024

	Intervention Event/n (%)	Control Event/n (%)	Odds Ratio (95% CI)	P Value
All-Cause Mortality	1153/21,612 (5.3%)	1127/21,622 (5.2%)	1.02 (0.94, 1.12)	0.568
Cardiac Death	85/21,612 (0.4%)	116/21,622 (0.5%)	0.73 (0.55, 0.97)	0.029
Low Ejection Fraction	340/21,612 (1.6%)	304/21,622 (1.4%)	1.12 (0.96, 1.31)	0.151
Hospitalization for ED Patients	4781/13,606 (35.1%)	4721/13,688 (34.5%)	1.03 (0.98, 1.08)	0.261
<b>STEMI–Related Diagnoses</b>				
STEMI with occluded vessel(s)	77/21,612 (0.4%)	68/21,622 (0.3%)	1.13 (0.82, 1.57)	0.453
Urgent coronary angiography	100/21,612 (0.5%)	86/21,622 (0.4%)	1.16 (0.87, 1.55)	0.303
All STEMI	107/21,612 (0.5%)	102/21,622 (0.5%)	1.05 (0.80, 1.38)	0.726
STEMI without coronary angiography for AI–potential STEMI	7/108 (6.5%)	16/101 (15.8%)	0.37 (0.14, 0.94)	0.036


Intervention vs. Control

In patients with STEMI, AI-ECG-assisted triage of STEMI decreased the door-to-balloon time, the ECG-to-balloon time and cardiac death. No differences were found regarding new-onset heart failure with reduced ejection fraction.





# ANATOMICAL ASSESSMENT: CORONARY-CT



- Amongst patients with suspected CAD, an abnormal **AI-QCT ischaemia** (a novel artificial intelligence-guided quantitative computed tomography ischaemia algorithm) result was associated with a two-fold increased adjusted rate of long-term death, MI, or unstable angine.
- AI-QCT ischaemia may be useful to improve risk stratification, especially amongst patients with no/non-obstructive CAD on coronary CTA.




# FUNCTIONAL ASSESSMENT: FFR-CT

## THE (RE-(EVOLUTION)) OF CCTA

Coronary CTA data set

Anatomic model of coronaries



Physiologic model of circulation



3-D FFR<sub>CT</sub> solution

Computation of coronary flow

Modeling maximal hyperaemia



Mass Conservation (1 equation):


$$\frac{\partial v_x}{\partial x} + \frac{\partial v_y}{\partial y} + \frac{\partial v_z}{\partial z} = 0$$

Momentum Balance (3 equations):


$$\rho \frac{\partial v_x}{\partial t} + \rho \left( v_x \frac{\partial v_x}{\partial x} + v_y \frac{\partial v_x}{\partial y} + v_z \frac{\partial v_x}{\partial z} \right) = -\frac{\partial p}{\partial x} + \mu \left( \frac{\partial^2 v_x}{\partial x^2} + \frac{\partial^2 v_x}{\partial y^2} + \frac{\partial^2 v_x}{\partial z^2} \right)$$

$$\rho \frac{\partial v_y}{\partial t} + \rho \left( v_x \frac{\partial v_y}{\partial x} + v_y \frac{\partial v_y}{\partial y} + v_z \frac{\partial v_y}{\partial z} \right) = -\frac{\partial p}{\partial y} + \mu \left( \frac{\partial^2 v_y}{\partial x^2} + \frac{\partial^2 v_y}{\partial y^2} + \frac{\partial^2 v_y}{\partial z^2} \right)$$

$$\rho \frac{\partial v_z}{\partial t} + \rho \left( v_x \frac{\partial v_z}{\partial x} + v_y \frac{\partial v_z}{\partial y} + v_z \frac{\partial v_z}{\partial z} \right) = -\frac{\partial p}{\partial z} + \mu \left( \frac{\partial^2 v_z}{\partial x^2} + \frac{\partial^2 v_z}{\partial y^2} + \frac{\partial^2 v_z}{\partial z^2} \right)$$



- **Computational Fluid Dynamics (CFD) and machine learning (AI)**
- **From typical CTA datasets**
- **No additional radiation**
- **No change in imaging protocol**
- **No additional medications**




From Gabara L. and Curzen N, Expert Analysis ACC. 2019.




# FFR-CT

## ADVANCE REGISTRY: CLINICAL EFFICACY AND IMPACT ON CLINICAL DECISION MAKING

*Reduction of unnecessary ICAs with no reduction in revascularization rates*



*Management plan change post CCTA & FFR-CT Analysis*




**66.9% of patients were re-classified!**

# FFR-CT


## ADVANCE REGISTRY: IMPACT ON OUTCOMES

CV death+MI stratified by  $FFR_{CT} > 0.80$  vs  $\leq 0.80$





C

CV death+MI at 1 year stratified by  $FFR_{CT}$  values




# FFR-CT

## PRECISE TRIAL: A RANDOMIZED CONTROLLED TRIAL EVALUATING 2,013 PATIENTS WITH CHEST PAIN



# FFR-CT

## 2024 ESC GUIDELINES ON CHRONIC CORONARY SYNDROMES



Vrints C et al. Eur Heart J. 2024.

Bom et al. Journal of Cardiovascular Computed Tomography 2021; 15:37–45

The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events:

- CCTA:
  - left main disease with  $\geq 50\%$  stenosis, three-vessel disease with  $\geq 70\%$  stenosis, or two-vessel disease with  $\geq 70\%$  stenosis, including the proximal LAD or one-vessel disease of the proximal LAD with  $\geq 70\%$  stenosis and  $FFR-CT \leq 0.8$ .

I

B

**Recommendation Table 13** — Recommendations for selection of initial diagnostic tests in individuals with suspected chronic coronary syndrome (see also Evidence Table 13)

In patients with a known intermediate coronary artery stenosis<sup>d</sup> in a proximal or mid coronary segment on CCTA, CT-based FFR may be considered.


IIb

B



# INTRAVASCULAR IMAGING: OCT vs. IVUS

**OCT:** An optical imaging modality that uses near-infrared light for high-resolution imaging of vessel anatomy, tissue microstructure and stents.






**IVUS:** An ultrasound imaging modality with high depth of penetration with more visibility of all three arterial layers and more appropriately true vessel size enabling larger-sized stent implantation.

	OCT	IVUS
Resolution	15 $\mu\text{m}$	150 $\mu\text{m}$
Penetration	2 mm	10 mm
Field of View	10 mm	10 mm
Frame Rate	100 FPS	15-30 FPS
Pullback Speed	75 mm/sec	0.5/1.0 mm/sec
Catheter Size	Sub 3F	3.2 F

# IMAGING-GUIDED PCI: META-ANALYSIS

## RELATIVE RISK REDUCTIONS WITH IMAGING-GUIDED VS. ANGIOGRAPHY-GUIDED PCI

20 randomized controlled trials (N=11,698)




# AI-DRIVEN INTRAVASCULAR IMAGING ALLOWS FOR AUTOMATED IN-DEPTH ASSESSMENT OF THE INTRACORONARY ANATOMY

Timeline  
(1977- Present)

## CORONARY ANGIOGRAPHY



1977: Andreas Gruentzig first PCI angiography<sup>1</sup>



9-14-1977

9-16-1977

## INTRAVASCULAR IMAGING




## AI-DRIVEN PCI GUIDANCE



1. Retrieved on Sept 2021 from: <https://www.pconline.com/About-PCR/40-years-angioplasty/Timeline/First-PTCA>.

2. Kubo, T. et al. (2013). OCT compared with IVUS in a coronary lesion assessment. *JACC: Cardiovascular Imaging*, 6(10), 1095-1104.

# THE INTERACTION BETWEEN TASKS SUPPORTED BY AI TOOLS FOR THE ASSESSMENT OF **VULNERABLE PLAQUES** IN CORONARY ARTERIES




Föllmer B et al. Nat Rev Cardiol. 2024;21(1):51-64.




# HUB MODEL FOR REMOTE PATIENT MONITORING

Spatz ES. et al. *N Engl J Med* 2024;390:346-56.

Cardiovascular conditions may require a period of intensive monitoring and medication adjustment. In this model of remote patient monitoring (RPM), a digital health bundle with remote management through a centralized hub may be prescribed.




# DIGITAL SOLUTIONS TO OPTIMIZE GUIDELINE-DIRECTED MEDICAL THERAPY PRESCRIPTION RATES IN PATIENTS WITH HEART FAILURE



# CHRONIC CORONARY SYNDROMES: LONG-TERM FOLLOW-UP

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy lifestyles and medical therapy.	I	A


Vrints C et al. Eur Heart J. 2024.



Vrints C et al. Eur Heart J. 2024.




# THE PROMISES AND PERILS OF MOBILE TECHNOLOGIES IN CARDIOVASCULAR CARE



Varma N et al. *J Am Coll Cardiol.* 2024;83(5:611-631).




# WEARABLE DIGITAL HEALTH TECHNOLOGIES: TRUST AND SECURITY



Patients' trust and security must be addressed to ensure that they are willing to share the data from their wearable DHTs. Societal issues that must be addressed to facilitate trust are listed, along with local health system strategies that are essential for trust and security.

# AI IN CARDIOVASCULAR DISEASES: **BENEFITS AND CONCERNS**



Shiely E et al., *Arrhythm Electrophysiol Rev.* 2022;11:e03.



*“How can you think about that with everything that’s going on in the field of A.I.?”*